pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN
Lxo Ireland Designated
Lxo Ireland Designated Activity Company
Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP
CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
- Status
- Public
- HQ
- CARLSBAD, CA, IE
- Programs
- 68
- Drugs
- 61
- Patents
- 201
Anterior lamellar nanostructured artificial human cornea.
Phase 2 · small molecule · Severe Trophic Corneal Ulcers Refractory to Conventional Treatment
Anterior lamellar nanostructured artificial human cornea. for Severe Trophic Corneal Ulcers Refractory to Conventional Treatment is a Phase 2 program (small_molecule) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).
Internal code CAH/Ulc/2010
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lxo Ireland Designated Activity Company
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Severe Trophic Corneal Ulcers Refractory to Conventional Treatment
- Status
- completed
- Trials
- 1